Acute Onset Neurological Disorders during Pregnancy: A Literature Review

Doenças neurológicas de início durante a gravidez: análise crítica da literatura

Zita Ferraz1 Joana Parra2 Ana Luísa Areia1,3 Elsa Vasco1 Paulo Moura1,3

1 Obstetrics Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
2 Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
3 Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal

Address for correspondence Zita da Costa Ferraz, MD, PhD, Obstetrics Unit, Centro Hospitalar e Universitário de Coimbra - Rua Miguel Torga, 3030-165 Coimbra, Portugal (e-mail: ferrazzita@gmail.com).


Abstract

Objectives To characterize the most common peripheral and central neurological disorders during pregnancy.

Methods Original research and review of the literature on neurological complications during pregnancy. We searched for keywords related to the topic on different databases.

Results Pregnancy involves physiological changes that can trigger peripheral neurological and/or central nervous system pathologies, which can sometimes be associated with hypertensive disorders. A definitive diagnosis of neurological disorders can be made according to the trimester of pregnancy and the clinical findings. Carpal tunnel syndrome and peripheral facial palsy are common peripheral neurological disorders, more frequent in the second half of pregnancy. Central nervous disorders are more complex and a precise diagnosis must be made in order to improve perinatal outcomes, provide correct management and treatment and to prevent acute and long-term complications.

Conclusions It is possible to achieve a precise diagnosis, management and treatment of neurological disorders during pregnancy, but these require a multidisciplinary approach, crucial to improve perinatal outcomes.

Keywords

► pregnancy
► Bell’s palsy
► carpal tunnel syndrome
► headache
► cerebrovascular complications
► management

Resumo

Objetivos Caracterizar as alterações neurológicas centrais e periféricas mais comuns durante a gravidez.

Métodos Foi efetuada uma revisão da literatura acerca de complicações neurológicas durante a gravidez. Foram utilizadas diversas bases de dados usando palavras-chave relacionadas com o tema.

Resultados A gravidez envolve alterações fisiológicas que podem desencadear alterações neurológicas periféricas e/ou do sistema nervoso central, por vezes associadas a distúrbios hipertensivos. Um diagnóstico definitivo pode ser feito tendo...
Acute Onset Neurological Disorders during Pregnancy

Ferraz et al.

Introduction

Pregnancy is associated with anatomical and physiological changes, such as decreased vascular resistance, increased vascular permeability and cardiac output. These are essential to accommodate plasma volume expansion and guarantee perfusion of vital organs. Nevertheless, fluctuations in estrogen concentration can increase coagulation factors and lead, consequently, to an increased risk of thromboembolism. In these situations, elevated levels of progesterone induce vasodilation, vascular stasis and edema, which further increase the risk of thromboembolism.

The risk of hypertension caused by the higher resistance in maternal systemic blood vessels, which occurs in cases of preeclampsia, can adversely affect blood flow in many organs (including liver, kidneys, brain and placenta). Thus, women with preeclampsia and eclampsia have an increased risk of complications, such as pulmonary edema, placental abruption, aspiration pneumonia, renal failure, hepatic failure and stroke.

Some peripheral neuropathies (carpal tunnel syndrome, peripheral facial palsy) and some central neurological disorders (seizure, migraine, cerebrovascular malformations, epilepsy) may be more frequent during pregnancy due to an exacerbation of a preexisting neurological condition, or by an acute onset of a neurological disorder associated with physiological changes engendered by pregnancy (such as headache or vascular disorders).

Both peripheral and central neurological disorders can occur during the three trimesters of pregnancy. So, an early and accurate diagnosis is essential to improve pregnancy management, treatment and subsequent perinatal outcomes.

The aim of this review is to describe and characterize the most common peripheral and central neurological disorders during pregnancy and subsequent management and treatment thereof.

Methods

A systematic search was conducted using Medline, PubMed, MeSH and ScienceDirect. Combinations of the search terms “pregnancy,” “carpal tunnel syndrome,” “Bell’s palsy,” “headache,” “cerebral thrombosis,” “cerebral hemorrhage,” “diagnosis,” “management” and “treatment” were used. A total of 76 articles were included in this review, published between 2005 and 2017.

Results

Both peripheral and central neurological disorders can occur during the three trimesters of pregnancy and arise from specific changes occurring in each trimester (Table 1).

Peripheral Neurological Disorders

Carpal tunnel syndrome and peripheral facial palsy are common examples of minor peripheral neurological disorders in pregnancy. However, factors that predispose to neuropathies should be considered in pregnant women, including diabetes, thyroid disorders, and/or inherent neuropathies (Charcot-Marie-Tooth disease).

Although most neuropathies are usually reversible, associated disabilities or morbidities can limit function and require therapy.

Carpal tunnel syndrome is a group of symptoms caused by compression of the median nerve in the carpal tunnel, characterized by numbness, tingling and weakness in the thumb, index, middle, half of the ring finger and parts of the palm of the hand (supplied by the median nerve). The incidence varies from 2% to 70% during pregnancy depending on the diagnostic method and the physician.

Complaints occur most commonly in the second and third trimester (Table 1), in the morning and at night. They are associated with venous congestion and/or nerve compression upon wrist flexion during sleep. Hormonal changes, fluid accumulation with a predisposition to edema, nerve hypersensitivity and glucose level fluctuations can all increase the risk of pregnant women developing symptoms of carpal tunnel syndrome. Diagnosis is clinical and could be confirmed by electrodiagnostic testing.

Conservative treatment is almost always appropriate and a complete recovery after pregnancy is the rule. In cases requiring intervention, first-line treatment includes overnight immobilization of the wrist with a splint in a neutral position or in slight extension. If necessary, local procedures such as an intracarpal steroid injection and surgery (with local anesthesia) are safe for mother and fetus.
Peripheral disorders can occur with or without aura. If de novo MH occurs, it is more likely to occur with aura. In general, 50–75% of women with preexisting MH without aura see an improvement or complete remission during pregnancy. This fact suggests that high stable placental estrogen levels, mainly during the second and third trimesters of pregnancy, could be beneficial to this pathology. Studies have shown no difference in the incidence or course of MH between primiparous and multiparous women.

The increase in estrogen levels can be the source of MH with aura in susceptible women. In general, women with MH (with or without aura) can be assured that there are no adverse effects on pregnancy’s outcome or maternal health. Nevertheless, some retrospective studies suggest that MH has been mentioned as a possible predictor of complications in pregnancy, including miscarriage, preeclampsia, eclampsia, congenital abnormalities, cerebral venous sinus thrombosis, stroke, and low birth weight; these links remain inconsistent due to poorly controlled studies.

**Imaging Studies**

Neuroradiology is important to exclude secondary causes of headache. Imaging findings are usually normal in migraine. The indications for imaging testing are the same as those for non-pregnant women. The exclusion of threatening secondary causes is essential, especially if “red flags” are present (Fig. 1). Magnetic resonance imaging (MRI) is safe during pregnancy; however, the use of gadolinium in pregnant women is not recommended due to insufficient evidence for safety.
controversial because it can cross the placenta (although it has not been shown to cause birth defects). Magnetic resonance imaging is recommended to assess the posterior fossa, while magnetic resonance arteriography (MRA) and magnetic resonance venography (MRV) are indicated to exclude vascular causes of headache.

Computed tomography (CT) scan without contrast is an imaging option in pregnancy in selected cases; however, the risk of in utero exposure to ionizing radiation limits its use. When imaging studies are indicated, MRI should be used due to its higher resolution, increased sensitivity, and lack of ionizing radiation. The use of CT scan should be considered in selected cases, due to its wider availability and lower cost. Contrast agents should be avoided, unless absolutely necessary.

**Symptomatic Treatment**
Medical therapy should be selected taking into consideration adverse effects on the fetus. Symptomatic treatment during pregnancy is challenging and a detailed discussion of the risks and benefits of each medical treatment is essential (►Table 2). First-line therapy includes an analgesic and an antiemetic drug. The pain management options for use during pregnancy described below are in accordance with the US Food and Drug Administration (FDA) recommendations.

**Analgesics**
Acetaminophen (category B for intravenous administration) is the analgesic of choice for short-term relief of mild to moderate pain during pregnancy, and it is considered a safe drug at therapeutic doses of ≤4 g per day for an adult. An analgesic dose of acetylsalicylic acid (100mg/day) is safe in the first and second trimesters, but it should be used with caution near term (category D) due to its effect on platelet function, causing an increased risk of prolonged labor, postpartum hemorrhage, neonatal bleeding and premature closure of the fetal ductus arteriosus. Metamizol/dipyrone (category C), by oral or intravenous route, has been demonstrated to be effective in the treatment of migraine attacks, but the risk of agranulocytosis, renal failure and hypotension limits its use. Also, it has been associated with Wilms tumor, with risk of infant leukemia and there are several case reports suggesting its association with oligohydramnios and closure of the ductus arteriosus when used in the third trimester. It was taken off the US market, but it is still available in some European and Latin American countries.

**Non-Steroidal Antiinflammatory Drugs (NSAIDs)**
Studies do not satisfactorily support their use during pregnancy, except for ibuprofen (category C prior to 30 weeks and category D ≥30 weeks). Moreover, persistent exposure to NSAIDs, or any level of exposure to them after 30 weeks, is associated with an increased risk of premature closure of the fetal ductus arteriosus and oligohydramnios due to its inhibitory effect on prostaglandin activity.

**Triptans**
In contrast to analgesics, the efficacy of triptans is due to the specifically targeted pathogenesis of MH. The safety of triptans during pregnancy is still questionable and their sustained use is discouraged unless no other treatment is successful. Sumatriptan and rizatriptan (category B) have not been associated with congenital abnormalities or adverse outcomes and, to date, the risk of major malformations has been reported to be equal to the baseline risk in the general population (1% to 3%).
Antiemetics
Metoclopramide (category B) is commonly used in pregnancy for its antiemetic and gastric prokinetic effects.\(^25,26\) Extrapyramidal reactions are the most common acute side effect of metoclopramide with a reported incidence of 0.2%.\(^37,38\) Promethazine (category C in the first trimester and B thereafter) and prochlorperazine (category C) are dopamine receptor antagonists and can be used combined with NSAIDs or opioids;\(^39\) the latter may be associated with congenital heart defects and cleft palate.\(^19\) Ondansetron (category B) should not be used as first-line treatment. Beginning the treatment after 10 weeks of gestational age (GA) minimizes the risks of teratogenicity.\(^40\)

Cerebrovascular disorders are uncommon in reproductive-aged women. Pregnancy-induced physiological changes increase the risk of cerebral venous thrombosis, as also do the existence of preeclampsia/eclampsia and thrombophilia.\(^39,41–43\)

Cerebral venous thrombosis
Most pregnancy-related cerebral venous thrombosis (CVT) occur in the third trimester of pregnancy and puerperium (\(\rightarrow\) Table 1), accounting for 27 to 57% of all pregnancy-related strokes.\(^44,45\) Common presenting complaints include headache (typically sub-acute), focal neurological deficits, seizures, altered mental status and signs of high intracranial pressure such as papilloedema.\(^22,46\) History of a previous extracerebral venous thrombotic event is also associated with adverse pregnancy outcomes and has a 3–4-fold higher risk of venous thrombotic event during subsequent pregnancies.\(^44\)

Headache with focal neurological signs or seizures should raise the suspicion of CVT.\(^2,21\) Diagnosis is based on neuroimaging, with MRI being preferable to CT scan because of its higher resolution, sensitivity, and lack of ionizing radiation.\(^16,21,24\) In most cases, CT results will show nonspecific edema or infarction. Fetal outcomes after a CVT seem to be favorable and have low mortality rates.\(^43,44,47,48\) Pregnancy and the puerperium are periods of high-risk for thrombotic complications, particularly the third trimester of pregnancy and the first four weeks postpartum.\(^49–52\)

Anticoagulation during pregnancy must be individualized according to the co-existence of risk factors.\(^13,43,47\) Evidence suggests the use of maintenance anticoagulation for a period of 3 months in presence of high risk factors, and for at least 6–12 months in patients with idiopathic cases (potential etiologies include paroxysmal atrial fibrillation, patent foramen ovale, atherosclerotic plaques of the aortic arch, congenital and acquired prothrombotic states) and women with mild hereditary thrombophilia (heterozygous factor V Leiden or prothrombin G20210A mutation). Indefinite anticoagulation should be reserved to patients with idiopathic cases, recurrent episodes, and to those with high-risk thrombophilia (antithrombin, protein C or protein S deficiency, homozygous factor V Leiden or prothrombin G20210A mutation, antiphospholipid antibodies and combined abnormalities).\(^52–55\)

Hemorrhagic disorders
Bleeding of an arteriovenous malformation (AVM) is a cerebrovascular complication that is noticeable in younger women (20–25 years-old) and earlier in pregnancy (15–20 weeks

### Table 2 Symptomatic drugs used during pregnancy

<table>
<thead>
<tr>
<th>Drug</th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen/Paracetamol (≤ 4 g) Metamizol (Dipyrone)**</td>
<td>☺</td>
<td>ID</td>
<td>ID</td>
</tr>
<tr>
<td>Aspirin (≤ 100 mg/day) Ibuprofen Diclofenac Naproxen</td>
<td>(☺)</td>
<td>(☺)</td>
<td>Avoid</td>
</tr>
<tr>
<td>Metoclopramide Promethazine Ondansetron Prochlorperazine* Chlorpromazine* Prednisolone*</td>
<td>(☺)</td>
<td>(☺)</td>
<td>(☺)</td>
</tr>
<tr>
<td>Ergotamine</td>
<td>CI</td>
<td>CI</td>
<td>CI</td>
</tr>
<tr>
<td>Almotriptan Eletriptan Frovatriptan Zolmitriptan</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
</tr>
<tr>
<td>Naratriptan Rizatriptan Sumatriptan</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

Abbreviations: CI, contraindicated; ID, insufficient data; ?, limited data, but **probably safe**.

☺, no evidence of harm; (☺) data suggest unlikely to cause harm.

*., for emergency treatment of migraine not responding to standard measure
**., contraindicated in the US market. Available in some European and Latin-American countries.
of GA); in contrast, aneurysm rupture occurs more commonly in older women (30–35 years-old) and between 30–40 weeks of GA. Possible mechanisms include hormonal changes (that lead to a predisposition to the development, enlargement and rupture of an aneurysm), increase in cardiac output by 60% in the second trimester and higher blood volume in the third trimester, which all increase the risk of aneurysm rupture. Women generally present with an abrupt onset of a severe and unusual headache (thunderclap headache), nausea and vomiting, photophobia, syncope and focal neurological deficits. If brain CT without contrast does not provide a diagnosis, a lumbar puncture should be performed. For hemorrhagic AVM, cerebral angiography is necessary. An unruptured AVM in pregnancy, with no bleeding risk factors (aneurysm, venous ectasia), should be followed conservatively. In contrast, an emergency surgery is necessary for a bleeding cerebral AVM, particularly if the existence of a hematoma causes worsening of neurological symptoms or cerebral herniation.

Endovascular embolization for cerebral AVM in pregnancy should be performed per clinical manifestations and angiographic features. Several studies reported that this procedure during pregnancy is safe and effective. The radiation dose of endovascular and stereotactic radiotherapy during pregnancy is also safe. However, non-radiation procedures are preferred during pregnancy. In cases of unruptured AVM, vaginal delivery or caesarean section should depend on obstetric criteria.

Subarachnoid hemorrhage (SAH) occurs most commonly because of ruptured aneurysm or AVM. The frequency of SAH in pregnancy is 5.8:100,000 deliveries in the United States of America. The most common symptom is severe headache. Computed tomography scan is the diagnostic exam of choice as it can identify hyperdense signal provided by extravasated blood in the basal cisterns. It is unclear whether the risk of SAH is increased during pregnancy and the puerperium and there are no formal studies to support optimal obstetric management of pregnant women with SAH. Mode of delivery is based solely on obstetric criteria.

Discussion

Pregnancy is associated with a risk of thromboembolism and can lead to neurological disorders. So, women who present with acute neurological symptoms require a meticulous diagnostic evaluation. Carpal tunnel syndrome and peripheral facial palsy are common examples of peripheral neurological disorders, which occur more often in the third trimester due to physiologic changes during pregnancy. Generally, surgery is not required and medical treatment is satisfactory. However, some women can maintain symptoms in the first three years post-partum.

Central nervous system disorders are more complex. The acknowledgment of symptoms and imaging testing, if necessary, are extremely important to attain the correct diagnosis. Magnetic resonance imaging is safe during pregnancy and CT scan should be avoided and used only if absolutely necessary. Both diagnosis and management of headache in pregnant women present several challenges. Migraine is the most common and well-studied type of headache and it is divided in two main subtypes: with aura, occurring predominantly in the third trimester; and without aura, most common in the first trimester, improving in the third trimester. In contrast, ~8% of women experience increased frequency or intensity of MH during pregnancy. Data showed no difference in the incidence or course of MH between primiparous and multiparous women. Symptomatic treatment during pregnancy is challenging and should be selected taking into consideration adverse effects on the fetus. The literature is consensual that analgesic (such as acetaminophen) and antiemetic drugs (such as metoclopramide) are the first-line therapy of choice. Recently, a preliminary study with recommended doses of acetaminophen was performed to investigate the potential effect of perinatal exposure on metabolic function in mice offspring. The authors concluded that acetaminophen may be associated with impaired glucose metabolism, increased plasma insulin level, and reduced liver glycogen content; however, further investigation is warranted to demonstrate this potential association. Generally, acetaminophen is considered a safe drug at therapeutic doses. However, acetaminophen overdose remains the most common cause of acute liver failure in the western world, and women must be warned that safe dosage needs to be respected. Some triptans (sumatriptan and rizatriptan) can be used, although their safety in pregnancy remains unknown. Non-steroidal anti-inflammatory drugs should be avoided mainly in the third trimester due to its association with premature closure of the foetal ductus arteriosus, oligohydramnios and risk of postpartum hemorrhage. For all these facts, medical treatment has to be conscientious, maintaining doses as low as possible, individualized to each woman. The prognosis of migraine (with or without aura) is favorable and literature does not provide evidence of complications. Nevertheless, perinatal adverse outcomes can occur in women with no evidence of remission or amelioration of migraine attacks. So, MH should be considered a potential risk factor in obstetric care and has to be managed by a multidisciplinary team.

Cerebral venous thrombosis frequently occurs during the third trimester and puerperium. The literature is not consensual about the risk of recurrence of CVT. Generally, fetal outcome of a pregnancy after a CVT seems to be favorable. The risk of stroke is elevated during the first year postpartum, lowering in subsequent years. However, history of a previous extracerebral venous thrombotic event is associated with adverse pregnancy outcome and has a 3–16-fold higher risk of venous thrombotic event during subsequent pregnancies. Cerebral venous thrombosis recurrence is 80-fold higher than the baseline risk described in general population studies. Mehraein et al studied the outcomes of 21 pregnancies with a previously treated CVT. Low-dose heparin was given subcutaneously during the course of 5 of these pregnancies, while no anticoagulation was given during the course of the remaining 14 pregnancies.
and puerperium periods. None of patients had recurrence of CVT during pregnancy and puerperium and no extracerebral vascular thromboembolism occurred. They concluded that a history of CVT does not justify a negative advice on pregnancy in women. Current guidelines of the Royal College of Obstetricians and Gynaecologists for the prevention of thromboembolism defend that all women should undergo a documented assessment of risk factors in early pregnancy or pre-pregnancy and risk assessment should be repeated intrapartum or immediately postpartum. Women with a previous episode of thromboembolism (associated with antithrombin deficiency or with recurrent episodes of thromboembolism) should be offered thromboprophylaxis with a higher dose of anticoagulant therapy antenatally and for 6 weeks postpartum (or until returned to oral anticoagulant therapy after delivery). Instead, women in whom the original episode of thromboembolism was unprovoked/idiopathic or related to estrogen (for instance, in pregnancy) should be offered thromboprophylaxis with anticoagulant therapy throughout the antenatal period. In terms of the peripartum period, a recent integrated analysis of two prospective studies concluded that antithrombin concentrate is safe and effective in reducing venous thromboembolism if administered over an average period of 4 days. As so, more studies are warranted to define the real risk of thromboembolism in subsequent pregnancies and anticoagulation therapy to prevent complications and risk of recurrence in future pregnancies; the risk of thromboembolism should be discussed with women at risk and the reasons for individual recommendations explained.

Arteriovenous malformation complications are more frequent in the first trimester, contrasting to aneurysm rupture, which occurs more commonly in the second half of pregnancy, both can lead to SAH. It is consensual that imaging investigation is vital and, during pregnancy, MRI is preferable to CT scan because of its higher resolution, sensitivity, and lack of ionizing radiation. In addition, MRV and MRA can be performed for the exclusion of vascular disorders and contrast agents cause adverse fetal effects and should avoided, unless absolutely necessary for an accurate diagnosis.

Data are consistent that the appropriate delivery in cases of neurological complications remains undefined and the decision of the way should be based on obstetric criteria if the hemorrhagic risk has been removed.

After appropriate diagnosis, proper treatment and follow-up are extremely important. In cases of cerebrovascular complications, the management and follow-up by a multidisciplinary team is mandatory. With scientific advances, the ability to diagnose and discriminate different causes of acute neurological symptoms is likely to progress. Because most of these conditions are rare, an early transfer to a Reference Centre and a multidisciplinary approach is essential to improve maternal and fetal outcomes.

Conclusions

Pregnancy is characterized by anatomic and physiologic changes that can trigger or potentiate neurological complaints. According to the pregnancy trimester, clinical findings, maternal age and risk factors, a definitive diagnosis of central or peripheral neurological disorders can be made, with appropriate management. An adequate treatment and supervision of these conditions are extremely important, with a multidisciplinary approach being essential to improve outcomes and prevent acute and long-term complications.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare they have no conflict of interest.

References

14 Juan YC, Au HK, Hsu JJ, Ma PC, Liu WM, Jeng CJ. Bell palsy and preeclampsia superimposed on chronic hypertension. Taiwan J Obstet Gynecol 2010;49(02):223–224
15 Murthy JM, Saxena AB. Bell’s palsy: Treatment guidelines. Ann Indian Acad Neurol 2011;14(Suppl 1):S70–S72
Duong S, Bozzo P, Nordeng H, Einarson A. Safety of triptans for
Ndour DD. Maternal use of non-steroidal antiinflammatory drugs and
Facchinetti F, Allais G, Nappi RE, et al. Migraine is a risk factor for
Cephalalgia 2009;29(03):286–292
Contag SA, Mertz HL, Bushnell CD. Migraine during pregnancy: is
it more than a headache? Nat Rev Neurol 2009;5(08):449–456
Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and
migraine during pregnancy and puerperium: the Migra-study.
Schoen JC, Campbell RL, Sadosty AT. Headache in pregnancy: an
approach to emergency department evaluation and management.
West J Emerg Med 2015;16(02):291–301
Sasidharan PK. Cerebral vein thrombosis misdiagnosed and mismanaged.
Thrombosis 2012;2012:210676
Cripe SM, Frederick IO, Qiu C, Williams MA. Risk of preterm
delivery and hypertensive disorders of pregnancy in relation to
maternal co-morbid mood and migraine disorders during preg-
Hacein-Bey L, Varelas PN, Ulmer JL, Mark LP, Raghavan K, Pro-
venzale JM. Imaging of cerebrovascular disease in pregnancy and
the puerperium. AJR Am J Roentgenol 2016;206(01):26–38
pharmacological prophylaxis of migraine in pregnancy: part II.
Cephalalgia 2010;97:137-159
Robbins MS, Farmakidis C, Dayal AK, Lipton RB. Acute headache
diagnosis in pregnant women: a hospital-based study. Neurology
2015;85(12):1024–1030
Turner DP, Smitherman TA, Eisenach JC, Penzien DB, Houle TT.
Predictors of headache before, during, and after pregnancy: a
Nieto de los Rios J, Vazquez de Anda CT, Echeverria C, et al. Migraine in 100
Nie Q, Guo P, Ge J, Qiu Y. Cerebral venous sinus thrombosis with
malignant hypertension in pregnancy—a poignant allegory of an unu-
Yis U, Ozdemir D, Duman M, Unal N. Metoclopramide induced
12(03):117–119
Bordini CA, Roesler C, Carvalho DdES, et al. Recommendations for
the treatment of migraine attacks - a Brazilian consensus. Arq
Neuropsiquiatri 2016;74(03):262–271
Kennedy D. Ondansetron and pregnancy: Understanding the data.
Arai N, Tabuse M, Nakamura A, Miyazaki H. Malignant isolated
cortical vein thrombosis with type II protein S deficiency: a case
report. BMC Neurol 2016;16:69
Hosley CM, McCullough LD. Acute neurological issues in preg-
Aracic N, Roje D, Jakus IA, Bakotin M, Stefanovic V. The impact of
inherited thrombophilia types and low molecular weight heparin
treatment on pregnancy complications in women with previous
Meng R, Ji X, Wang X, Ding Y. The etiologies of new cases of
clinical and epidemiologic implications for future research.
Neurology 2015;85(03):117–118
Chen X, Li A, Zhang Q, Li J, Wei X. Clinical and therapeutic
aspects of post-partum cerebral thrombophlebitis. Pan Afr Med J
2016;25:123–129
and thrombotic events in pregnancy: single-center experience.
Berti C, O’Brien K, Tibbles CD. Diagnosis of acute
neurological emergencies in pregnant and post-partum women.
Lancet Neurol 2013;12(02):175–185
pharmacological prophylaxis of migraine in pregnancy: part II.
Cephalalgia 2010;97:137-159
Robbins MS, Farmakidis C, Dayal AK, Lipton RB. Acute headache
diagnosis in pregnant women: a hospital-based study. Neurology
2015;85(12):1024–1030
Turner DP, Smitherman TA, Eisenach JC, Penzien DB, Houle TT.
Predictors of headache before, during, and after pregnancy: a
Nieto de los Rios J, Vazquez de Anda CT, Echeverria C, et al. Migraine in 100
Nie Q, Guo P, Ge J, Qiu Y. Cerebral venous sinus thrombosis with
malignant hypertension in pregnancy—a poignant allegory of an unu-
aspects of post-partum cerebral thrombophlebitis. Pan Afr Med J
2016;9:23–26
Cantu-Brito C, Arauz A, Aburto Y. Barinagarrenemteria F, Ruiz-
Sandoval JL, Baizabal-Cardvallo JF. Cerebrovascular complications
during pregnancy and postpartum: clinical and prognosis ob-
servations in 240 Hispanic women. Eur J Neurol 2011;18(06):
819–825
Edlow JA, Caplan LR, O’Brien K, Tibbles CD. Diagnosis of acute
neurological emergencies in pregnant and post-partum women.
Lancet Neurol 2013;12(02):175–185
and thrombotic events in pregnancy: single-center experience.
Gupta R, Aggarwal M, Pathil S, Vyas V. Cerebral venous thrombosis
2015;14(03):43–45
Shah M, Agarwal N, Gala NB, Prestigiacomo CJ, Gandhi CD.
Management of dural venous sinus thrombosis in pregnancy.
EJVES Extra 2014;27(05):e41–e42
Nie Q, Guo P, Ge J, Qiu Y. Cerebral venous sinus thrombosis with
cerebral hemorrhage during early pregnancy. Neurosciences (Riyadh)
2015;20(01):48–51
Heart Association Stroke Council and the Council on Epidemiol-
omy and Prevention. Diagnosis and management of cerebral
venous thrombosis: a statement for healthcare professionals
from the American Heart Association/American Stroke Associa-
tion. Stroke 2011;42(04):1158–1192
Berezcki DJr, Szegedi N, Szakács Z, Gubuz I, May Z. Cryptogenic
Einhäupl K, Stam J, Bousser MG, et al; European Federation of
Neurological Societies. EFNS guideline on the treatment of cere-
blood flow and susceptibility to infant leukemia with maternal exposure to
dipyone during pregnancy. Cancer Epidemiol Biomarkers Prev
2010;19(12):3037–3043
Shastri AT, Abdulkarim D, Clarke P. Maternal diclofenac medica-
tion in pregnancy causing in utero closure of the fetal ductus
Ndour DD. Maternal use of non-steroidal antiinflammatory drugs and
Duong S, Bozzo P, Nordeng H, Einarrow A. Safety of triptans for
migraine headaches during pregnancy and breastfeeding. Can Fam Physician 2010;56(06):537–539
Jo YY, Kim YB, Yang MR, Chang YJ. Extrapyramidal side effects


